Jim Broderick

Jim Brod­er­ick reels in a $100M Se­ries B to ex­plore a 'new and big' an­gle of im­mune reg­u­la­tion

When Jim Brod­er­ick launched Mass­a­chu­setts-based Palleon Phar­ma­ceu­ti­cals in 2015, he had an of­fice in Cam­bridge’s Kendall Square, a bit of seed mon­ey, and a blank can­vas.

He set out to in­no­vate with­in a new space in im­munol­o­gy, and re­cruit­ed sci­en­tif­ic co-founders Car­olyn Bertozzi, a Stan­ford pro­fes­sor, and Paul Crock­er, a pro­fes­sor and the head of the cell sig­nal­ing and im­munol­o­gy di­vi­sion at the Uni­ver­si­ty of Dundee, Scot­land, to help him do it.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.